In light of this challenge, PRF1 expression was introduced into target cells directly, via a liposomal nanocarrier encapsulating a PRF1 expression vector driven by the prostate-specific antigen (PSA) promoter, so PRF1 expression was restricted to the prostate cancer cells. Here, KLK3 is linked to prostate carcinoma.